Anti-PD-L1 antibody [EPR20529]
Anti-PD-L1 항체 [EPR20529]
- RabMAb
- Recombinant
- KO Validated
- 20ul selling size
- 각 태그의 뜻
5
(5 리뷰들)
|
(132 제품이 사용된 논문 )
- KO validated for confirmed specificity
- Biophysical QC for unrivalled batch-batch consistency
- Over 70 publications
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)
ab213480 staining PD-L1 in RAW264.7 from Mouse macrophage cell line transformed with Abelson murine leukemia virus by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 100% Methanol. Samples were incubated with ab213480 at 0.4 μg/ml. AlexaFluor®488 Goat anti-Rabbit (ab150077) was used as the secondary antibody at 2 μg/ml. Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594)(ab196889) was used as counterstain at 2.5 μg/ml. DAPI used as nuclear counterstain. Confocal image showing membranous staining on RAW 264.7 cells treated with IFN-γ (100 ng/ml) for 24 hours.
- IP
Supplier Data
Immunoprecipitation - Anti-PD-L1 antibody [EPR20529] (AB213480)
PD-L1 was immunoprecipitated from 0.35 mg of Mouse placenta lysate with ab213480 at 1/30 dilution.
Western blot was performed from the immunoprecipitate using ab213480 at 1/500 dilution.
VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1,000 dilution.
Lane 1 : Mouse placenta lysate, 10 μg (Input).
Lane 2 : ab213480 IP in mouse placenta lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab213480 in mouse placenta lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 seconds.
All lanes:
Immunoprecipitation - Anti-PD-L1 antibody [EPR20529] (ab213480)
Predicted band size: 33 kDa
Observed band size: 55-60 kDa
false
- WB
Supplier Data
Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
Blocking/Dilution buffer : 5% NFDM/TBST.
The molecular weight observed is consistent with what has been described in the literature. PMID : 15353579.
All lanes:
Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 1/1000 dilution
All lanes:
Mouse placenta lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/ko/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 33 kDa
Observed band size: 40-60 kDa
false
Exposure time: 15s
- WB
Lab
Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
This WB was performed by using YCA-R20529(BF)-111A H3L2 YR120921PJ, 1 : 5000 dilution. Working concentration : 0.402 μg/ml.
Blocking buffer and concentration : 5% NFDM/TBST
Diluting buffer and concentration : 5% NFDM/TBST
All lanes:
Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 1/5000 dilution
Lane 1:
Untreated RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg
Lane 2:
RAW264.7 treated with 100 ng/ml IFN gamma for 48 h, whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/ko/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 33 kDa
Observed band size: 40-60 kDa
false
Exposure time: 37s
- WB
AbReview78135****
Western blot - Anti-PD-L1 antibody [EPR20529] (AB213480)
The mAb is specific for mouse mPDL1 and does not recognise hPDL1. As expected a specific 48kDa band is observed in RAW264.7 and MEFS cell extract after Interferon-gamma treatment. No bands are observed in RAW264.7 and MEFS WT and in MEFS KO with and without Interferon-gamma treatment.
All lanes:
Western blot - Anti-PD-L1 antibody [EPR20529] (ab213480) at 100 µg
Lane 1:
HEK mPDL1 cell lysate at 20 µg
Lane 2:
HEK hPDL1 cell lysate at 20 µg
Lane 3:
HEK CL7 at 20 µg
Lane 4:
RAW 264.7 Wild-type (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate at 100 µg
Lane 5:
RAW 264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate treated with Interferon-gamma at 100 µg
Lane 6:
MEF Wild-type (Mouse embryonic fibroblast cell line) whole cell lysate at 100 µg
Lane 7:
MEF (Mouse embryonic fibroblast cell line) whole cell lysate treated with Interferon-gamma at 100 µg
Lane 8:
MEF mPDL1 KO cell lysate at 100 µg
Lane 9:
MEF mPDL1 KO treated with Interferon-gamma at 100 µg
Predicted band size: 33 kDa
Observed band size: 48 kDa
false
Exposure time: 5min
This image is courtesy of an anonymous collaborator.
관련 conjugated 항체와 다양한 조성의 항체 (1)
-
Anti-PD-L1 antibody [EPR20529] - BSA and Azide free
Reactivity 정보
제품 세부 정보
Anti-PD-L1 antibody [EPR20529] (ab213480) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IP and WB.
Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR20529] (ab213480) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
The specificity of Anti-PD-L1 antibody [EPR20529] (ab213480) has been confirmed by Western Blot testing in PD-L1 knockout MEF (mouse embryonic fibroblast) cells.
Anti-PD-L1 antibody [EPR20529] (ab213480) has 5 independent reviews from customers.
Anti-PD-L1 antibody [EPR20529] (ab213480) specifically detects PD-L1 (UniProt ID: Q9EP73; Molecular weight: 31kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR20529 - ab223141.
Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
특성 및 보관 정보
제형
Purification 테크닉
보관 버퍼
배송 시 보관 조건
적절한 단기 보관 기간
적절한 단기 보관 조건
적절한 장기 보관 조건
분주 정보
보관 정보
추가 정보
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
제품 프로토콜
- Visit the General protocols
- Visit the Troubleshooting
타겟 정보
대체 명칭 보기
제품이 사용된 논문 (132)
Recent publications for all applications. Explore the 전체 목록 and refine your search
Cell reports. Medicine :102924 PubMed42468534
2026
Applications
Unspecified application
Species
Unspecified reactive species
Journal of nanobiotechnology 23:648 PubMed41074162
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 16:8804 PubMed41038820
2025
Applications
Unspecified application
Species
Unspecified reactive species
Neoplasia (New York, N.Y.) 69:101222 PubMed40882404
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell communication and signaling : CCS 23:374 PubMed40836297
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal for immunotherapy of cancer 13: PubMed40789740
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer management and research 17:1503-1512 PubMed40727589
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 16:4564 PubMed40379682
2025
Applications
Unspecified application
Species
Unspecified reactive species
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12:e04860 PubMed40364727
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature genetics 57:680-693 PubMed40069506
2025
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com